Takeda Pharmaceutical Company Limited

In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.

In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.

In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million.

Johnson & Johnson’s (JNJ) Imbruvica generated revenue of $705.0 million in the third quarter.

In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid.

Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

Celgene’s (CELG) Revlimid and Pomalyst generated revenues of $2.2 billion and $453 million, respectively in the first quarter.

In 1Q18, Amgen’s (AMGN) Kyprolis revenue grew 17% YoY (year-over-year) to $222 million from $190 million, primarily due to higher unit demand in international markets.

Pfizer (PFE) plans to produce a second-generation cyclin-dependent kinase (or CDK) inhibitor in 2018.

Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest.

On March 29, 2018, Shire (SHPG) was trading at $149.39, which represented a 21% rise from its 52-week low of $123.73.

In 4Q17, Novartis’s (NVS) Gleevec generated revenues of $448 million, which reflected a ~41% decline on year-over-year (or YoY) basis and 1% growth quarter-over-quarter.

In 4Q17, JNJ’s Velcade reported revenues of $271.0 million compared to $274.0 million in 4Q16, which reflected an ~1.0% YoY decline.

In fiscal 2017, Johnson & Johnson’s (JNJ) blockbuster drug Remicade generated revenues of $6.3 billion, which reflected an ~9.3% decline year-over-year.

In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis.

In 4Q17, Pfizer’s (PFE) Bosulif generated revenues of $70 million, which reflected ~52% growth on a YoY (year-over-year) basis.

In December 2017, Gilead Sciences (GILD) presented updated results from its ongoing phase-1/2 ZUMA-3 trial.

In 1Q17, 2Q17, and 3Q17, Tasigna generated revenues of $411 million, $463 million, and $482 million, respectively.

In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

In December 2017, Bristol-Myers Squibb presented new data from the phase 2 CA180-372 trial.

in 1Q17, 2Q17, and 3Q17, Kyprolis generated revenues of $190.0 million, $211.0 million, and $207.0 million, respectively.

In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.

In 3Q17, Johnson & Johnson’s (JNJ) Velcade generated revenues of $273 million, a ~10% decline on a year-over-year (or YoY) basis and a 6% decline quarter-over-quarter.

Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.

Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

Sucampo Pharmaceuticals has granted licenses to commercialize a generic or authorized generic of Amitiza in the United States to Par Pharmaceutical and Dr. Reddy’s Laboratories.

In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.

In 3Q17, Bristol-Myers Squibb’s (BMY) Sprycel generated revenues of $509 million, an 8% increase on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.

In 3Q17, Novartis’s (NVS) Tasigna reported revenues of $482 million, which with ~9% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter).

EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.

In 1H17, Novartis’s (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.

Blincyto’s revenue trends In 2Q17, Amgen’s (AMGN) Blincyto generated revenues of ~$43 million, which represented ~43% growth on a YoY (year-over-year) basis. Blincyto (blinatumomab) is an injection for the treatment of adults and children with relapsed or refractory B-cell precursor ALL (acute lymphoblastic leukemia). For more on Blincyto and its revenue prospects, please refer to […]

Kyprolis’s revenue trends In 2Q17, Amgen’s (AMGN) Kyprolis generated revenues of ~$211 million, which reflected ~23% growth on a YoY (year-over-year) basis and ~11% growth QoQ (quarter-over-quarter). In 2Q17, Kyprolis witnessed a ~20% volume growth QoQ, and its launch in international markets contributed heavily to the company’s overall YoY revenue growth. In 2Q17, in the US, Kyprolis […]

In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.

In 2Q17, Celgene’s (CELG) Revlimid generated revenues of ~$2.0 billion, which reflected ~20% growth year-over-year and ~8% growth quarter-over-quarter.

In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

In 1Q17, Celgene (CELG) reported revenues of ~$3.0 billion, an increase of ~18% year-over-year (or YoY).

In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.

In 1Q17, Kyprolis generated revenues of ~$190 million compared to $154 million in 1Q16.

Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.

Gastrointestinal franchise prescriptions In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) drugs Xifaxan, Uceris, Apris, and Relistor reported solid year-over-year (or YoY) growth in prescriptions, of around 18%, 6%, 4%, and 1%, respectively. Relistor growth trends Since the launch of the oral version of Relistor in 4Q16, the drug has witnessed a 13% rise in total […]

Gastrointestinal business In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) franchise saw its revenue fall due to the loss of patent protection for drugs Zegerid and Glumetza in the US market. Furthermore, the authorized generic version of Zegerid was transferred from Valeant’s Branded Rx segment to the Diversified Products segment. However, these negative trends were […]

Despite more competition and pressures, Merck’s Januvia franchise continued to maintain its leadership in the DPP-4 inhibitor class of diabetes drugs.

In 3Q16, Valeant Pharmaceuticals’s (VRX) Gastrointestinal product segment witnessed a drop in revenues due to unfavorable changes in drug pricing.

The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.

In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.

Teva Pharmaceutical’s (TEVA) strategy of selectively focusing on certain countries has enabled it to see double-digit organic growth in the growth markets.

Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.

Due to significant unmet demand and limited competition in the women’s health segment, AbbVie expects Elagolix to become a blockbuster therapy.

Consumer discretionary, information technology, and telecom services form the core of SAESX. Combined, these three form 55% of the fund’s portfolio.

Financials were the biggest negative contributors to CNJFX’s total returns in the first four months of 2016.

Celgene has been working on its immunomodulatory backbone drugs to develop combination therapies for use in treating all lines of multiple myeloma.

Adcetris is an anti-CD30 monoclonal antibody that targets CD30, which is a marker for lymphoma.

Japan is the second-largest individual pharmaceutical market in the world. It accounts for less than 10% of the total global pharma market.

The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.

The NHI revises drug prices every two years. During fiscal 2016, a 6.8% reduction in drug prices is expected.

The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

In fiscal 2015, Lialda added $684.4 million to Shire’s (SHPG) top line, reflecting an 8% annual increase in sales. This was supported by a 10% rise in prescription volume.

Saxenda, a glucagon-like peptide-1 (or GLP-1) analog therapy, holds 31% market share for branded anti-obesity drugs.

In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.

Xifaxan is indicated for IBS with diarrhea and hepatic encephalopathy. It’s Valeant’s largest revenue generator, contributing ~7.5% of total revenues.

The Voya Japan TOPIX Index Portfolio – Class A (IJIAX) fell 0.9% in December 2015 from the previous month. In the three- and six-month periods ended December 31, the fund has risen 7.3% and fallen 4.0%, respectively.

BIAJX fell 3.7% in December 2015 from the previous month. In the three-month and six-month periods ended December 31, 2015, the fund has risen 8.3% and fallen 6.4%, respectively.

Aside from the risky generic pharmaceutical industry, Mylan faces company-specific business risks like country risk, foreign exchange risk, and M&A risk.

In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.

Headquartered in the UK, Mylan is one of the biggest players in the generic pharmaceutical industry. It was founded by Milan Puskar and Don Panoj in 1961.

The FDA approval of Empliciti was based on the results of a phase III study termed Eloquent-2.

On November 30, 2015, Bristol-Myers Squibb (BMY) and AbbVie (ABBV) announced that the FDA has approved Empliciti for treatment of patients with multiple myeloma.

Based on the success of its clinical trial and its superior clinical profile, Takeda’s Ninlaro is expected to prove a tough competitor to other MM drugs.

Brown Advisory-WMC Japan Alpha Opportunities Fund doesn’t target a specific segment by market capitalization. Instead, it intends to be benchmark agnostic.

Performance evaluation The Brown Advisory-WMC Japan Alpha Opportunities Fund (BIAJX) fell by 6.7% in September 2015 from the previous month. In the three- and six-month periods ending September 30, the fund fell by 13.5% and 7.7%, respectively. However, in the YTD (year-to-date) period, the fund was up by 2.9%. For all periods mentioned above except […]

According to projections by Novo Nordisk (NVO), targeting the obesity market by pharmaceutical companies is about 4–5 DKK (Danish krone currency) in value.